Viltolarsen

Viltolarsen
Viltolarsen.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Viltolarsen is a pharmaceutical drug used in the treatment of Duchenne muscular dystrophy (DMD), a severe type of muscular dystrophy characterized by rapid progression of muscle degeneration. Viltolarsen is specifically designed to target mutations in the dystrophin gene that are amenable to exon 53 skipping.

Mechanism of Action

Viltolarsen is an antisense oligonucleotide that works by binding to exon 53 of the dystrophin pre-mRNA. This binding causes the exon to be skipped during mRNA splicing, resulting in the production of a truncated but functional dystrophin protein. This mechanism is intended to partially restore the function of the dystrophin protein in patients with specific genetic mutations.

Clinical Use

Viltolarsen is indicated for the treatment of patients with Duchenne muscular dystrophy who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. It is administered via intravenous infusion and is typically given on a weekly basis.

Side Effects

Common side effects of Viltolarsen include injection site reactions, upper respiratory tract infections, and fever. Patients receiving Viltolarsen should be monitored for potential adverse reactions, and the drug should be used with caution in patients with renal impairment.

Development and Approval

Viltolarsen was developed by Nippon Shinyaku and NS Pharma. It received accelerated approval from the United States Food and Drug Administration (FDA) in 2020 based on its ability to increase dystrophin production in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Related pages

• Duchenne muscular dystrophy
• Antisense oligonucleotide
• Dystrophin
• Exon skipping

• 
  Viltolarsen